Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 31 studies | 39% ± 17% | |
classical monocyte | 26 studies | 35% ± 14% | |
monocyte | 19 studies | 35% ± 13% | |
non-classical monocyte | 13 studies | 32% ± 8% | |
neutrophil | 12 studies | 41% ± 12% | |
microglial cell | 12 studies | 37% ± 19% | |
oligodendrocyte | 11 studies | 27% ± 9% | |
myeloid cell | 11 studies | 40% ± 18% | |
dendritic cell | 10 studies | 28% ± 7% | |
adipocyte | 10 studies | 79% ± 13% | |
type II pneumocyte | 9 studies | 31% ± 10% | |
alveolar macrophage | 8 studies | 51% ± 18% | |
conventional dendritic cell | 7 studies | 23% ± 6% | |
hepatocyte | 6 studies | 80% ± 15% | |
epithelial cell | 6 studies | 25% ± 9% | |
epithelial cell of proximal tubule | 5 studies | 19% ± 5% | |
fibroblast | 5 studies | 26% ± 8% | |
mononuclear phagocyte | 4 studies | 42% ± 17% | |
endothelial cell | 4 studies | 30% ± 11% | |
kidney loop of Henle epithelial cell | 4 studies | 20% ± 5% | |
cardiac muscle cell | 4 studies | 25% ± 3% | |
ionocyte | 3 studies | 35% ± 5% | |
retinal pigment epithelial cell | 3 studies | 25% ± 7% | |
inflammatory macrophage | 3 studies | 35% ± 12% | |
cholangiocyte | 3 studies | 48% ± 23% | |
GABAergic neuron | 3 studies | 35% ± 7% | |
glutamatergic neuron | 3 studies | 35% ± 9% | |
club cell | 3 studies | 17% ± 1% | |
leukocyte | 3 studies | 21% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 97% | 15363.52 | 86 / 89 | 99% | 132.36 | 890 / 901 |
liver | 100% | 74611.54 | 226 / 226 | 95% | 212.24 | 385 / 406 |
lung | 97% | 25213.32 | 558 / 578 | 94% | 58.96 | 1087 / 1155 |
skin | 91% | 17102.40 | 1652 / 1809 | 92% | 44.35 | 435 / 472 |
breast | 88% | 45165.43 | 404 / 459 | 92% | 65.61 | 1024 / 1118 |
prostate | 77% | 9214.89 | 189 / 245 | 100% | 171.83 | 502 / 502 |
thymus | 65% | 5875.65 | 427 / 653 | 89% | 38.41 | 536 / 605 |
esophagus | 49% | 4332.55 | 713 / 1445 | 87% | 44.97 | 159 / 183 |
bladder | 43% | 3821.00 | 9 / 21 | 88% | 52.11 | 443 / 504 |
adrenal gland | 52% | 4399.67 | 133 / 258 | 76% | 27.81 | 175 / 230 |
uterus | 49% | 3812.54 | 83 / 170 | 76% | 35.95 | 348 / 459 |
stomach | 49% | 4203.41 | 177 / 359 | 73% | 24.82 | 210 / 286 |
pancreas | 8% | 563.35 | 25 / 328 | 96% | 57.02 | 170 / 178 |
ureter | 0% | 0 | 0 / 0 | 100% | 19.37 | 1 / 1 |
muscle | 100% | 67227.03 | 802 / 803 | 0% | 0 | 0 / 0 |
adipose | 99% | 62409.22 | 1195 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 95414.50 | 900 / 929 | 0% | 0 | 0 / 0 |
spleen | 95% | 18635.90 | 228 / 241 | 0% | 0 | 0 / 0 |
intestine | 26% | 2678.35 | 250 / 966 | 67% | 24.73 | 353 / 527 |
brain | 14% | 1343.17 | 379 / 2642 | 78% | 28.65 | 553 / 705 |
tonsil | 0% | 0 | 0 / 0 | 91% | 36.95 | 41 / 45 |
lymph node | 0% | 0 | 0 / 0 | 86% | 39.99 | 25 / 29 |
eye | 0% | 0 | 0 / 0 | 83% | 47.62 | 66 / 80 |
heart | 74% | 11559.40 | 638 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 55% | 7059.36 | 734 / 1335 | 0% | 0 | 0 / 0 |
ovary | 3% | 221.61 | 6 / 180 | 39% | 9.97 | 167 / 430 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007584 | Biological process | response to nutrient |
GO_0034201 | Biological process | response to oleic acid |
GO_0033211 | Biological process | adiponectin-activated signaling pathway |
GO_0014070 | Biological process | response to organic cyclic compound |
GO_0008610 | Biological process | lipid biosynthetic process |
GO_0000038 | Biological process | very long-chain fatty acid metabolic process |
GO_0015908 | Biological process | fatty acid transport |
GO_0042178 | Biological process | xenobiotic catabolic process |
GO_0019432 | Biological process | triglyceride biosynthetic process |
GO_0044539 | Biological process | long-chain fatty acid import into cell |
GO_0001676 | Biological process | long-chain fatty acid metabolic process |
GO_0120162 | Biological process | positive regulation of cold-induced thermogenesis |
GO_0010747 | Biological process | positive regulation of long-chain fatty acid import across plasma membrane |
GO_0035338 | Biological process | long-chain fatty-acyl-CoA biosynthetic process |
GO_0005778 | Cellular component | peroxisomal membrane |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0004467 | Molecular function | long-chain fatty acid-CoA ligase activity |
GO_0090434 | Molecular function | oleoyl-CoA ligase activity |
GO_0043539 | Molecular function | protein serine/threonine kinase activator activity |
GO_0070251 | Molecular function | pristanate-CoA ligase activity |
GO_0047676 | Molecular function | arachidonate-CoA ligase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0050197 | Molecular function | phytanate-CoA ligase activity |
Gene name | ACSL1 |
Protein name | Long-chain-fatty-acid--CoA ligase 1 (EC 6.2.1.3) (Acyl-CoA synthetase 1) (ACS1) (Arachidonate--CoA ligase) (EC 6.2.1.15) (Long-chain acyl-CoA synthetase 1) (LACS 1) (Long-chain acyl-CoA synthetase 2) (LACS 2) (Long-chain fatty acid-CoA ligase 2) (Palmitoyl-CoA ligase 1) (Palmitoyl-CoA ligase 2) (Phytanate--CoA ligase) (EC 6.2.1.24) Acyl-CoA synthetase long chain family member 1 long-chain-fatty-acid--CoA ligase (EC 6.2.1.3) Long-chain-fatty-acid--CoA ligase (EC 6.2.1.15) (EC 6.2.1.3) (Acyl-CoA synthetase) (Long-chain acyl-CoA synthetase) |
Synonyms | LACS1 FACL2 LACS FACL1 LACS2 |
Description | FUNCTION: Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation . Preferentially uses palmitoleate, oleate and linoleate . Preferentially activates arachidonate than epoxyeicosatrienoic acids (EETs) or hydroxyeicosatrienoic acids (HETEs) (By similarity). . FUNCTION: Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation. . FUNCTION: Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation. . FUNCTION: Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation. . FUNCTION: Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation. . |
Accessions | H0Y9Z9 ENST00000504900.5 P33121 ENST00000706368.1 [P33121-3] H0Y9U7 ENST00000706366.1 [P33121-3] B7Z3Z9 ENST00000503407.6 [P33121-2] ENST00000503407.6 Q108N2 E7EPM6 ENST00000506733.5 ENST00000706369.1 [P33121-1] ENST00000505492.2 D6RG07 ENST00000515030.5 [P33121-1] ENST00000507295.5 ENST00000513317.5 [P33121-3] ENST00000706370.1 Q108N1 ENST00000504342.5 [P33121-1] ENST00000706367.1 [P33121-1] A0A994J7S4 D6RER0 ENST00000281455.7 [P33121-1] ENST00000454703.6 |